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Abstract
Primary influenza pneumonia has a high mortality rate during
pandemics, not only in immunocompromised individuals and
patients with underlying comorbid conditions, but also in young
healthy adults. Clinicians should maintain a high index of suspicion
for this diagnosis in patients presenting with influenza-like
symptoms that progress quickly (2 to 5 days) to respiratory
distress and extensive pulmonary involvement. The sensitivity of
rapid diagnostic techniques in identifying infections with the
pandemic 2009 H1N1v influenza strain is currently suboptimal.
The most reliable real-time reverse transcriptase-polymerase chain
reaction molecular testing is available in limited clinical settings.
Despite 6 months of pandemic circulation, most novel H1N1v
pandemic strains remain susceptible to oseltamivir. Ensuring an
appropriate oxygenation and ventilation strategy, as well as prompt
initiation of antiviral therapy, is essential in management.
Introduction
As the novel swine-origin influenza A (H1N1)v global
pandemic is under way, the medical community has already
experienced an increase in hospitalizations from influenza-
related complications in many geographic regions. Primary
viral pneumonia is recognized as the most severe pulmonary
manifestation of influenza. While uncommon during seasonal
epidemics, the syndrome has been well documented during
the H2N2 pandemic of 1957-1958 and is thought to be
responsible for much of the mortality associated with the
young healthy adult population during the 1918 H1N1
pandemic [1]. This paper reviews the clinical aspects of
influenza and primary influenza pneumonia that may be of
most interest to the practicing physician in the 2009
pandemic environment.
Epidemiology
Seasonal influenza epidemics occur each year as a result of
minor changes in the antigenic characteristics of the hemag-
glutinin and neuraminidase glycoproteins of the influenza
viruses (antigenic drift) [2]. The morbidity and mortality
associated with seasonal influenza outbreaks are significant,
especially in older patients, who incur more than 90% of the
influenza-related mortality each year [3]. Factors contributing
to their increased vulnerability include a decline in cell-
mediated and humoral immune responses, a reduction in lung
compliance and respiratory muscle strength, a diminished
cough reflex associated with normal aging, the frequent
presence of multiple comorbid conditions, nutritional deficien-
cies, and in the case of residents of long-term care facilities,
greater exposure risk due to close living quarters and shared
caregivers [4,5].
Influenza pandemics occur less frequently, as a result of
major changes in the surface glycoproteins of the virus
(antigenic shift). The emerging novel influenza strain then
easily spreads into an immunologically susceptible
population. Consequently, pandemics are characterized by a
shift in mortality toward the otherwise young and healthy 18-
to 35-year-old adults, with relative sparing of older patients,
as evidenced by epidemiological analyses of the 1918
influenza A pandemic [6]. This is likely due to the persistence
of immunological memory in older patients after previous
exposures to H1-type viruses similar to the pandemic strain
[7,8]. The virulence of the pandemic strain may also play a
role, as demonstrated by recent experiments with the highly
fatal 1918 influenza strain [9].
Preliminary data from the 2009 H1N1 pandemic suggest a
similar shift in age-related mortality. An analysis of 532 cases
of 2009 pandemic H1N1 influenza A in the US, for example,
has revealed that 60% of the cases occurred in patients not
older than 18 years of age and that only 5% occurred in
patients older than 50 years [10]. In the cohorts recently
tested, the modest extent of immunological memory in older
patients was confirmed by the presence of serum cross-
reactive antibodies to the pandemic H1N1 influenza A strain
found in 33% of the adults older than 60 years of age versus
6% to 9% of the adults 18 to 64 years of age and none of the
children [11].
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Influenza attack rates during seasonal epidemics vary
between 10% and 20% but can be much higher during pan-
demics. For example, an analysis of the pandemic 2009
H1N1 influenza A outbreak in La Gloria, Veracruz, found
clinical attack rates of 29% in adults older than 15 years and
61% in children younger than 15 years of age [12]. However,
these rates may be different in geographic areas of low
population density.
Groups at high risk for severe disease and complications
secondary to 2009 pandemic H1N1 influenza A include
patients with underlying pulmonary (asthma) and cardiac
comorbid conditions, some immunosuppressive states,
pregnancy and post-partum states, diabetes mellitus, obesity
[13,14], and, in children, prior neurological disabilities [15].
Severe primary H1N1 influenza pneumonia can also affect
young adults without any underlying comorbidities [14].
Transmission and infectiousness
Person-to-person transmission occurs primarily through
droplet spread via small particle-sized aerosols generated by
coughing, sneezing, or talking [16]. Airborne transmission
should be considered in those patients exposed to aerosol-
generating techniques, such as intubation or mechanical
ventilation.
The incubation period is usually 24 to 48 hours. In the
absence of antiviral treatment, viral shedding starts within
24 hours before the onset of symptoms and continues for
approximately 5 days in healthy adults [17]. Viral shedding can
last longer in children, patients with extensive comorbidities,
older patients, patients who undergo mechanical ventilation,
and immunocompromised hosts [18-20]. The infectious
period can be significantly reduced by the use of antiviral
medications within the first 48 to 96 hours of illness  [20].
Pathogenesis
After inhalation, the virus is deposited onto the respiratory
tract epithelium, where it attaches to ciliated columnar
epithelial cells via its surface hemagglutinin. Local host
defenses, such as mucociliary clearance, or secretion of
specific secretory IgA antibodies can remove some of the
virus particles. However, if mucociliary clearance is impaired
(as in smokers [21] or older patients [22]) or secretory anti-
influenza IgA antibodies are absent (as in no antecedent
exposure to the virus), infection continues unabated [23].
Respiratory epithelial cells are invaded, and viral replication
occurs. Newer viruses then infect larger numbers of epithelial
cells, shut off the synthesis of critical proteins, and ultimately
lead to host cell death [24].
In patients with uncomplicated influenza, bronchoscopy
typically reveals diffuse inflammation and edema of the larynx,
trachea, and bronchi, and biopsy may show cellular infiltration
with lymphocytes and histocytes and desquamation of the
ciliated columnar epithelium [25]. In patients with severe
influenza infections that progress to primary viral pneumonia,
the involvement of the respiratory tree is extensive, with
necrotizing tracheobronchitis, ulceration and sloughing of the
bronchial mucosa [26], hyperemic alveolar capillaries with
intra-alveolar hemorrhage, infiltration of alveolar spaces with
fluid, fibrin, and cellular exudates, and lining of the alveoli with
acellular hyaline membranes [1]. Autopsies from patients with
primary influenza pneumonia confirmed bilateral severe
hemorrhagic pneumonitis with interstitial inflammation, diffuse
alveolar damage, and heavy viral loads observed in the
periphery of the lungs.
Clinical manifestations
The clinical features of uncomplicated influenza are virtually
indistinguishable from those of other respiratory viral infect-
ions. Influenza is classically characterized by an abrupt onset
of headache, high-grade fever, chills, dry cough, pharyngeal
irritation, myalgias, malaise, and anorexia. The fever lasts an
average of 3 days (range of 2 to 8 days). The cough, initially
nonproductive and nonpurulent, may persist for weeks.
Bronchial hyper-reactivity and small-airway dysfunction are
often present in influenza virus infection. In the presence of
asthma or structural lung disease, wheezing may be a
prominent manifestation [24]. Vomiting and diarrhea, while
rare in seasonal influenza, have been frequently reported in
infections with the 2009 pandemic influenza A H1N1v strain
[10], particularly in children.
The clinical presentation of influenza in the immuno-
compromised host may be more subtle and manifest only as
coryza; similarly, the classic fever symptom may be absent in
the older patient, who may present only with lethargy,
confusion, anorexia, and cough [27]. Influenza pneumonia
and respiratory complications in patients with Th1 defects,
such as HIV infection, are uncommon.
Pneumonia and the acute respiratory distress syndrome
(ARDS) account for the majority of severe morbidity and
mortality that accompany pandemic influenza infection [14].
Pneumonia may occur as a continuum of the acute influenza
syndrome when caused by the virus alone (primary
pneumonia) or as a mixed viral and bacterial infection after a
delay of a few days (secondary pneumonia) [28]. Identifying
patients who are more likely to develop severe complications
from influenza pneumonia requires a high clinical vigilance.
Commonly used pneumonia severity assessment tools, such
as the Pneumonia Severity Index [29] or CURB65 [30], are
not useful in deciding which patients to hospitalize in the
context of primary influenza pneumonia since these tools have
not been developed and validated during a pandemic
scenario. Thus, careful triage in the emergency department
and early identification of young patients with decreased
oxygen saturation, respiratory rate above 25, concomitant
diarrhea, or hypotension are crucial. Elevated lactate
dehydrogenase, creatine phosphokinase, and creatinine at
hospital admission may also serve as prognostic indicators ofsevere disease [14]. C-reactive protein and procalcitonin are
increased during this acute lung injury stage of early
fibroproliferation.
The most ominous cases are those infections that progress
rapidly to ARDS and multilobar alveolar opacification. These
patients usually present with gradually increasing dyspnea
and severe hypoxemia after an antecedent of 2 to 5 days of
typical influenza symptoms [14]. The cough is usually produc-
tive of thin, often bloody, sputum with few cells. Hypoxemia
increases progressively to the point of respiratory failure
requiring intubation and mechanical ventilation, often after
only one day of hospitalization [14].
The radiological appearance of primary influenza pneumonia
can be difficult to distinguish on chest x-ray from pulmonary
edema, given the presence of perihiliar congestion and hazy
opacification, at least in the lower lobes (Figure 1a,b). Pleural
effusions may also be present. Computed tomography scans
(Figure 2) can add further diagnostic insight and may be
useful to differentiate primary viral pneumonia from
bronchiolitis and interstitial pneumonias, which occur
frequently in children and young adults but have a benign
outcome. Concomitant myopericarditis should be excluded
by echocardiography. Concurrent pulmonary emboli, as
suggested by early case reports from hospitalized patients
with pandemic influenza A H1N1v 2009 in the US [13], may
further contribute to clinical deterioration in some patients.
However, the occurrence of concomitant pulmonary emboli
has not been reproduced in other geographic regions so far.
Bacterial co-infection, though uncommonly reported in the
early stages of the 2009 H1N1 pandemic, may be more
prevalent than initially thought. A recent analysis of lung
specimens from 77 fatal cases of pandemic H1N1v 2009
infection found a prevalence of concurrent bacterial pneu-
monia in 29% of these patients [31]. The most common co-
infecting bacterial pathogens were pneumococcus, Staphylo-
coccus aureus, and Streptococcus pyogenes, with a median
duration of illness of 6 days [31].
Laboratory diagnosis
The real-time reverse transcriptase-polymerase chain reaction
(rRT-PCR) Swine Flu Panel for detection of pandemic H1N1
influenza, developed by the Centers for Disease Control and
Prevention (Atlanta, GA, USA) and distributed to many
laboratories in US and worldwide, is a reliable and timely
method of diagnosing the pandemic strain [32,33]. The viral
culture, while the gold standard in influenza diagnostics,
takes several days before the results are known [24]. The
direct fluorescent antigen influenza test was recently reported
to have a sensitivity of 93% compared with the rRT-PCR
[34], but the test requires considerable technical expertise in
addition to a fluorescent microscope. The commonly used
point-of-care rapid influenza tests provide results in less than
1 hour but are of only modest sensitivity for seasonal
influenza viruses (63%) [35] and unacceptably insensitive for
the detection of pandemic H1N1 influenza [35,36]. Thus, for
the majority of clinicians practicing during the 2009-2010
influenza pandemic, the access to a reliable and timely
diagnostic modality may still be limited. As such, it is
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Figure 1
Chest x-rays of a patient with primary H1N1 (swine-origininfluenza A) influenza pneumonia on day 1 (a) and day 6 (b) of hospitalization.reassuring to know that the patients presenting during
influenza epidemics with both cough and fever within the first
48 hours of symptom onset are very likely to have actual
influenza (79% positive predictive value) [37].
Management
The majority of patients with primary influenza pneumonia
require ventilatory support. Mortality is high but can be
decreased with an optimal protective ventilatory strategy
(tidal volume of not more than 6 mL per kilogram of predicted
body weight, with a plateau airway pressure goal of not more
than 30 cm H2O), as shown in Acute Respiratory Distress
Syndrome Network clinical trials; this strategy is therefore
recommended in acute lung injury [38,39]. Maintaining an
adequate fluid balance is also important for survival in acute
lung injury. The hemodynamic status should be optimized by
appropriate repletion of intravascular volume deficits during
the early systemic inflammatory stage [40]. Once acute lung
injury has become established, a conservative fluid manage-
ment protocol, which was associated with beneficial effects
in clinical trials, should be considered [41,42]. In severe
refractory cases of primary influenza pneumonia, some
patients require venovenous extracorporeal membrane oxy-
genation support and continuous renal replacement for acute
renal failure.
Antiviral treatment should be initiated as soon as possible,
particularly in patients at high risk of complications. The
majority of treatment benefits are derived when antivirals are
initiated within the first 48 hours from onset of symptoms.
Unfortunately, most patients with primary viral pneumonia
receive oseltamivir after 3 to 8 days of influenza onset [14].
However, the experience with seasonal influenza suggests
that a reduction in mortality for hospitalized patients has been
documented even when oseltamivir was initiated after the first
48 hours following illness onset [43]. Thus, being out of the
ideal therapeutic window should not be a reason to withhold
antiviral treatment at any stage of active disease.
Both neuraminidase inhibitors (oseltamivir and zanamivir) are
active against the novel H1N1v 2009 pandemic influenza A
strain. The recommended adult dose for oseltamivir, con-
sidered the first-line therapy for H1N1 influenza infection, is
75 mg orally twice a day for a total of 5 days [44]. Dose
adjustment may be required in the presence of reduced
creatinine clearance, but the dosage should be maintained
for patients undergoing continuous venovenous hemodialysis.
A recent World Health Organization treatment guideline for
pharmacological management of 2009 pandemic H1N1v
influenza A recommends the consideration of higher doses of
oseltamivir (150 mg twice a day) and longer duration of
treatment for patients with severe influenza pneumonia or
clinical deterioration [44]. Since hospitalized patients can
shed influenza virus for prolonged periods of time, extending
antiviral treatment beyond the first 5 days of treatment in
cases of persistent influenza symptoms may be necessary.
However, clear guidelines for these circumstances have not
been established, and clinical trials examining the appropriate
treatment dose and duration for severe H1N1 influenza in
various patient populations are acutely needed.
Development of oseltamivir resistance in novel H1N1
influenza, though still exceedingly rare, has been reported
from several countries [45]. It should be suspected in
patients who remain symptomatic or have evidence of viral
shedding despite a full treatment course of oseltamivir.
Immunosuppression and prior exposure to oseltamivir, such
as receipt of prolonged post-exposure prophylaxis, increase
the risk for oseltamivir resistance [45]. Zanamivir remains an
effective therapeutic option for these cases. Zanamavir is also
indicated in the rare circumstance when an oral route for
oseltamivir administration is not available for critically ill
patients in the intensive care unit. The risk of bronchospam
rarely associated with zanamivir, particularly in patients with
underlying reactive airway disease, can be minimized by
concurrent bronchodilator administration.
Adamantanes (amantadine and rimantadine) have no activity
against the 2009 influenza A H1N1v pandemic strain. They
are effective for seasonal H1N1 influenza strains, which are
100% resistant to oseltamivir. Therefore, for patients
presenting with primary influenza pneumonia in geographic
regions where seasonal H1N1 strains are circulating in
addition to the novel H1N1 pandemic strain, amantadine or
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Figure 2
Computed tomography scan of the patient with primary H1N1 (swine-
origininfluenza A) influenza pneumonia whose chest x-rays appear in
Figure 1.rimantadine should be added to oseltamivir [46]. Rimantadine
is also associated with immunomodulatory effects.
Patients presenting with severe influenza pneumonia who may
have concurrent bacterial superinfection should also receive
antibacterial agents effective against the most common
etiologic pathogens, such as Streptococcus pneumoniae,
Streptococcus pyogenes, and Staphylococcus aureus, includ-
ing methicillin-resistant Staphylococcus aureus, according to
published guidelines in the management of community-
acquired pneumonia [47].
Corticosteroids remain controversial in persistent ARDS and
are not routinely recommended [48]. Further research is
required to clarify their impact on outcome. Whether other
adjunctive immunomodulatory therapies such as statins,
chloroquine, and fibrates could prove useful in the context of
an influenza pandemic [49] remains to be determined.
Conclusions
Primary influenza pneumonia caused by the 2009 pandemic
influenza A H1N1v strain, though rare, carries a high mortality.
The rapid progression from initial typical influenza symptoms
to extensive pulmonary involvement, with acute lung injury,
can occur both in patients with underlying respiratory or
cardiac morbidities and in young healthy adults, especially if
obese or pregnant. Prompt initiation of effective antiviral
treatment, appropriate oxygenation and ventilation support,
and antibacterial treatment in the case of concurrent bacterial
pneumonia are critical for survival. The most reliable and
timely diagnostic method for 2009 pandemic influenza A
H1N1v infection is the rRT-PCR developed by the Centers
for Disease Control and Prevention. Common ‘point-of-care’
rapid influenza tests are very insensitive. A negative test result
in a patient with clinical symptoms compatible with influenza
pneumonia does not accurately rule out influenza and should
not be a deterrent to prompt oseltamivir treatment during this
current pandemic. Further research is needed in order to
identify the immunological dysfunction and determine the
most effective dose and duration of oseltamivir as well as the
role of potential adjunctive agents in the treatment of primary
influenza pneumonia.
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